Implantable cardioverter-defibrillator

Pacemakers Global Market Size, Share & Trends Analysis Report 2022-2030, Featuring Osypka Medical, Boston Scientific, Zoll Medical, Medtronic and Cook Medical - ResearchAndMarkets.com

Retrieved on: 
Friday, January 28, 2022
Medical Devices, Health, Growth, CRT, USD, Heart failure, Implantable cardioverter-defibrillator, Atrial fibrillation, CVD, National Center for Medical Intelligence, Death, National Center for Biotechnology Information, COVID-19, Stroke, CAGR, Adult, Prevalence, CDC, Megasphaera, Degenerative disease, Arrhythmia, Convention (norm), Cardiac resynchronization therapy, Moyamoya disease, NCBI, Medical device, Pharmaceutical industry

The global pacemakers market size is anticipated to reach USD 5.94 billion by 2030.

Key Points: 
  • The global pacemakers market size is anticipated to reach USD 5.94 billion by 2030.
  • This growth is owing to various factors such as technological advancements and the increasing prevalence of cardiovascular devices.
  • Furthermore, the growing sedentary lifestyle coupled with the rising geriatric population is also anticipated to fuel the market growth during the projected period.
  • Product development, collaborations, partnerships, mergers and acquisitions, and regional expansion are a few of them
    Chapter 3 Pacemaker Market Variables, Trends, and Scope

2021 Cardiac Rhythm Management Devices Medical Devices Pipeline Product Landscape Report - ResearchAndMarkets.com

Retrieved on: 
Monday, January 10, 2022
Health, Medical Devices, Cardiology, Artificial cardiac pacemaker, ICD, Implantable loop recorder, Implantable cardioverter-defibrillator, CRT, Heart, Arrhythmia, CRM, Medical device, Pharmaceutical industry

The "Cardiac Rhythm Management Devices - Medical Devices Pipeline Product Landscape, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cardiac Rhythm Management Devices - Medical Devices Pipeline Product Landscape, 2021" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive information about the Cardiac Rhythm Management Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
  • Cardiac Rhythm Management (CRM) devices are those devices which are used to restore the natural synchronized pumping rhythm of the heart.
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
    The report enables you to:
    In-depth analysis of the product's current stage of development, territory and estimated launch date

Global Defibrillators Market Report 2021-2027: Industry Trends, Growth, Impact of COVID-19, Opportunities, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Monday, December 6, 2021
Health, Medical Devices, Cardiology, Patient, Cardiac arrest, Defibrillation, Adoption, External, Product, Automated external defibrillator, CAGR, Awareness, Dysthanasia, American Heart Association, Shock, COVID-19, SCA, Arrhythmia, Time-invariant system, Association, Implantable cardioverter-defibrillator, AED, Pads, Medical device

The "Defibrillators Market Size, Share, Global Forecast 2021-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Defibrillators Market Size, Share, Global Forecast 2021-2027, Industry Trends, Growth, Impact of COVID-19, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Global Defibrillators Market will be $18.01 Billion by 2027 from $12.87 Billion in 2021, growing at a CAGR of 5.76% during 2021-2027
    Worldwide, different types of defibrillators work in different ways.
  • Defibrillators are immensely useful in reviving sudden cardiac arrest; this further pushed for the demand for defibrillators in the pandemic situation.
  • By Product type, we have categorized the global defibrillator market into the Implantable Cardioverter Defibrillator and External Defibrillator market.

Global Active Implantable Medical Devices Market to 2027 - 44 Players Featured Including Abbott Laboratories, Boston Scientific and Cochlear Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 19, 2021
Biotechnology, Health, Medical Devices, CAGR, Implantable cardioverter-defibrillator, COVID-19, Growth, Medical device, Pet

The "Active Implantable Medical Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Active Implantable Medical Devices - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Implantable Cardioverter Defibrillators, one of the segments analyzed in the report, is projected to record a 6.6% CAGR and reach US$10.8 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $6.1 Billion, While China is Forecast to Grow at 6% CAGR
    The Active Implantable Medical Devices market in the U.S. is estimated at US$6.1 Billion in the year 2020.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$3.7 Billion by the year 2027.

MicroPort® Cardiac Rhythm Management Business Announces US$150 Million Series C Investment

Retrieved on: 
Tuesday, July 27, 2021
Medical technology, Cardiac electrophysiology, Branches of biology, Life sciences, Medical devices, Neuroprosthetics, Microport, Biomedical engineering, Embedded systems, Microport, Artificial cardiac pacemaker, Implantable cardioverter-defibrillator

SHANGHAI, July 27, 2021 /PRNewswire/ -- MicroPort Scientific Corporation ("MicroPort") announced that MicroPort Cardiac Rhythm Management Limited ("MicroPort CRM"), which is MicroPort's subsidiary focused on developing and commercializing implantable pacemaker and defibrillator devices and related technologies to manage cardiac rhythm disorders, has entered into definitive agreements in connection with its Series C financing with total investment proceeds of US$150 million.

Key Points: 
  • SHANGHAI, July 27, 2021 /PRNewswire/ -- MicroPort Scientific Corporation ("MicroPort") announced that MicroPort Cardiac Rhythm Management Limited ("MicroPort CRM"), which is MicroPort's subsidiary focused on developing and commercializing implantable pacemaker and defibrillator devices and related technologies to manage cardiac rhythm disorders, has entered into definitive agreements in connection with its Series C financing with total investment proceeds of US$150 million.
  • Hillhouse Capital Group and MicroPort will co-lead the Series C investment and will invest US$20 million and US$47 million, respectively.
  • After the completion of this transaction, MicroPort will continue to be the majority shareholder of MicroPort CRM.
  • Through its long-standing expertise in CRM, MicroPort CRM develops, manufactures and markets around the world cardiac pacemakers, implantable cardiac defibrillators, cardiac resynchronization systems and ECG diagnostic solutions for the management of cardiac rhythm disorders and heart failure.

Global Defibrillator Market (2020 to 2025) - Growth, Trends, and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, January 29, 2021
Health, Medical devices, Cardiology, Cardiac electrophysiology, Branches of biology, Medical technology, Medical devices, Medicine, Neuroprosthetics, Biomedical engineering, Prosthetics, Implantable cardioverter-defibrillator, Artificial cardiac pacemaker, Cardiac resynchronization therapy, Cardiomyopathy

The implantable cardioverter defibrillator (ICD) segment accounted for the largest share in the global market.

Key Points: 
  • The implantable cardioverter defibrillator (ICD) segment accounted for the largest share in the global market.
  • The ICDs are of three major types, namely transvenous ICDs, subcutaneous ICDs, and CRT with pacemaker and ICD function.
  • Moreover, according to the Australian Institute of Health and Welfare, in 2017, approximately 4,578 people died, due to heart failure and cardiomyopathy.
  • The increasing prevalence of cardiovascular diseases in the region is expected to drive the market growth, over the forecast period.

Global Wearable Cardioverter Defibrillator Market Outlook to 2028 - Players Include Element Science, Medtronic and Abbott Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, January 18, 2021
Medical devices, Health, Cardiac electrophysiology, Branches of biology, Medical technology, Medical devices, Medicine, Cardiology, Medical equipment, Wearable cardioverter defibrillator, Defibrillation, LifeVest, Implantable cardioverter-defibrillator

The "Global Wearable Cardioverter Defibrillator Market Outlook 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Wearable Cardioverter Defibrillator Market Outlook 2028" report has been added to ResearchAndMarkets.com's offering.
  • Wearable cardioverter defibrillators are wearable devices which are capable of administering electrical shock to the heart for preventing sudden cardiac death (SDC).
  • An external defibrillator is attached in the wearable cardioverter defibrillator to a vest that is worn by the patient.
  • The global wearable cardioverter defibrillator market consists of various segments that are segmented by indication, demography, end user, and by region.

Congestive Heart Failure Treatment Device Market Research Report by Product - Global Forecast to 2025 - Cumulative Impact of COVID-19

Retrieved on: 
Wednesday, October 14, 2020
Medical technology, Branches of biology, Cardiac electrophysiology, Medical devices, Medicine, Prosthetics, Neuroprosthetics, Biomedical engineering, Cardiac resynchronization therapy, Artificial cardiac pacemaker, Implantable cardioverter-defibrillator, Heart failure

Congestive Heart Failure Treatment Device Market Research Report by Product (Cardiac Resynchronization Therapy, Implantable Cardioverter Defibrillator, Pacemaker, and Ventricular Assist Device) - Global Forecast to 2025 - Cumulative Impact of COVID-19

Key Points: 
  • Congestive Heart Failure Treatment Device Market Research Report by Product (Cardiac Resynchronization Therapy, Implantable Cardioverter Defibrillator, Pacemaker, and Ventricular Assist Device) - Global Forecast to 2025 - Cumulative Impact of COVID-19
    This research report categorizes the Congestive Heart Failure Treatment Device to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Product, the Congestive Heart Failure Treatment Device Market studied across Cardiac Resynchronization Therapy, Implantable Cardioverter Defibrillator, Pacemaker, and Ventricular Assist Device.
  • What is the market size and forecast of the Global Congestive Heart Failure Treatment Device Market?
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Congestive Heart Failure Treatment Device Market during the forecast period?
  • What are the modes and strategic moves considered suitable for entering the Global Congestive Heart Failure Treatment Device Market?

Congestive Heart Failure Treatment Device Market Research Report by Product - Global Forecast to 2025 - Cumulative Impact of COVID-19

Retrieved on: 
Thursday, June 11, 2020
Medical technology, Cardiac electrophysiology, Branches of biology, Medicine, Medical devices, Prosthetics, Neuroprosthetics, Biomedical engineering, Cardiac resynchronization therapy, Artificial cardiac pacemaker, Implantable cardioverter-defibrillator, Heart failure

NEW YORK, June 11, 2020 /PRNewswire/ --Congestive Heart Failure Treatment Device Market Research Report by Product (Cardiac Resynchronization Therapy, Implantable Cardioverter Defibrillator, Pacemaker, and Ventricular Assist Device) - Global Forecast to 2025 - Cumulative Impact of COVID-19

Key Points: 
  • NEW YORK, June 11, 2020 /PRNewswire/ --Congestive Heart Failure Treatment Device Market Research Report by Product (Cardiac Resynchronization Therapy, Implantable Cardioverter Defibrillator, Pacemaker, and Ventricular Assist Device) - Global Forecast to 2025 - Cumulative Impact of COVID-19
    This research report categorizes the Congestive Heart Failure Treatment Device to forecast the revenues and analyze the trends in each of the following sub-markets:
    On the basis of Product, the Congestive Heart Failure Treatment Device Market is studied across Cardiac Resynchronization Therapy, Implantable Cardioverter Defibrillator, Pacemaker, and Ventricular Assist Device.
  • What is the market size and forecast of the Global Congestive Heart Failure Treatment Device Market?
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Congestive Heart Failure Treatment Device Market during the forecast period?
  • What are the modes and strategic moves considered suitable for entering the Global Congestive Heart Failure Treatment Device Market?

Thermedical Announces SERF VT Study Presented as Part of HRS 2020 Science Late-Breaking Clinical Trial Sessions

Retrieved on: 
Friday, May 8, 2020
Health, Clinical trials, Cardiology, Medical devices, Branches of biology, Circulatory system, Cardiac arrhythmia, RTT, Cardiovascular system, Medical devices, Neuroprosthetics, Ventricular tachycardia, Defibrillation, Catheter ablation, Implantable cardioverter-defibrillator, Ablation, Thermedical, the Heart Rhythm Society

Thermedical , a developer of thermal-ablation systems to treat ventricular tachycardia (VT), announced that results from a First-in-Human Early Feasibility Study (EFS) using the new Durablate catheter to treat VT were presented in the late-breaking clinical trial sessions at the Heart Rhythm Society (HRS) meeting today.

Key Points: 
  • Thermedical , a developer of thermal-ablation systems to treat ventricular tachycardia (VT), announced that results from a First-in-Human Early Feasibility Study (EFS) using the new Durablate catheter to treat VT were presented in the late-breaking clinical trial sessions at the Heart Rhythm Society (HRS) meeting today.
  • The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Durablate catheter to treat VT , a leading cause of sudden cardiac death worldwide.
  • The target study population consists of patients who have failed all current forms of treatment including Implantable Cardioverter Defibrillators (ICDs), medical therapy and other forms of ablation therapy.
  • The Early Feasibility Study is the first human use of the Durablate Catheter Ablation System in the U.S. and Canada.